[HTML][HTML] Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab
B Lakatos, BG Szabo, I Bobek, L Gopcsa… - Acta Microbiologica et …, 2021 - akjournals.com
Acta Microbiologica et Immunologica Hungarica, 2021•akjournals.com
Large randomized clinical trials in severe Coronavirus Disease 2019 (COVID-19) patients
have proven efficacy of intravenous tocilizumab. Our aim was to describe the laboratory
parameters predicting in-hospital mortality of patients with tocilizumab administration in
COVID-19 associated cytokine release syndrome (CRS).
have proven efficacy of intravenous tocilizumab. Our aim was to describe the laboratory
parameters predicting in-hospital mortality of patients with tocilizumab administration in
COVID-19 associated cytokine release syndrome (CRS).
Abstract
Large randomized clinical trials in severe Coronavirus Disease 2019 (COVID-19) patients have proven efficacy of intravenous tocilizumab. Our aim was to describe the laboratory parameters predicting in-hospital mortality of patients with tocilizumab administration in COVID-19 associated cytokine release syndrome (CRS).
akjournals.com
以上显示的是最相近的搜索结果。 查看全部搜索结果